07:00 , May 28, 2012 |  BioCentury  |  Finance

Carried away

Carried away Three out of four corporate VCs on a panel at last week's C21 BioVentures conference in Napa, Calif., said their compensation does not include carried interest. Any upside stays with the funds, which...
07:00 , May 28, 2012 |  BioCentury  |  Finance

AbbVie earlier

AbbVie earlier Early stage investor...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Abbott management update

Abbott Laboratories (NSYE:ABT), Abbott Park, Ill.   Business: Finance   Retiring: Jim Tyree as president of Abbott's Abbott Biotech Ventures Inc. subsidiary  ...
08:00 , Feb 13, 2012 |  BioCentury  |  Finance

Biotech investor, banker and analyst personnel changes

Venture tracks James Tyree is retiring as president of...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Financial News

NeuroGenetic Pharmaceuticals completes venture financing

NeuroGenetic Pharmaceuticals Inc. , Del Mar, Calif.   Business: Neurology   Date completed: 1/4/12   Type: Venture financing   Raised: Not disclosed   Investor: Abbott Biotech Ventures  ...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Financial News

AuraSense completes venture financing

AuraSense Therapeutics LLC , Evanston, Ill.   Business: Genomics   Date completed: 12/22/11   Type: Venture financing   Raised: Not disclosed   Investors: Abbott Biotech Ventures; individual investors  ...
01:35 , Dec 23, 2011 |  BC Extra  |  Financial News

AuraSense closes series B round

Gene therapy company AuraSense Therapeutics LLC (Evanston, Ill.) raised an undisclosed amount in a series B round. Investors included Abbott Laboratories (NYSE:ABT) subsidiary Abbott Biotech Ventures; Patrick Ryan, founder of Aon Corp. (NYSE:AON); David Walt,...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Financial News

Creabilis completes venture financing

Creabilis S.A. , Luxembourg, Luxembourg   Business: Inflammation, Autoimmune, Dermatology   Date completed: 10/4/11   Type: Venture financing   Raised: €15 million ($20 million)   Investors: Abbott Biotech Ventures; NeoMed; Sofinnova Partners; individual investors  ...
00:33 , Oct 5, 2011 |  BC Extra  |  Financial News

Creabilis raises EUR 15 million

Creabilis S.A. (Luxembourg, Luxembourg) raised EUR 15 million ($20 million) in a series B round led by Abbott Biotech Ventures. Existing investors Neomed; Sofinnova Partners; and individual investors also participated. Creabilis' lead product, CT327 ,...
07:00 , Jun 28, 2010 |  BioCentury  |  Emerging Company Profile

Arreseto: Blocking Fibroblasts

Arresto Biosciences Inc. is developing allosteric inhibitors of enzymes found in the extracellular matrix. Because the company's lead mAb inhibits the formation of pathologic stroma, it offers new mechanisms for treating cancer and fibrosis. In...